ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
8.46
-0.21 (-2.42%)
At close: Jul 31, 2026, 4:00 PM EDT
8.51
+0.05 (0.59%)
After-hours: Jul 31, 2026, 7:44 PM EDT
ADMA Biologics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, ADMA Biologics stock has a consensus rating of "Buy" and an average price target of $17. The average 1-year stock price forecast is 100.95% higher than the current stock price, while the lowest is $12 (+41.84%) and the highest is $21 (+148.23%).
Price Target: $17 (+100.95%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ADMA Biologics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Maintains $20 → $17 | Buy | Maintains | $20 → $17 | +100.95% | Jul 15, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $18 | Buy | Maintains | $18 | +112.77% | Jun 15, 2026 |
| Raymond James | Raymond James | Buy Initiates $21 | Buy | Initiates | $21 | +148.23% | Jun 10, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Downgrades $30 | Hold | Downgrades | $30 | +254.61% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
534.33M
from 510.17M
Increased by 4.74%
Revenue Next Year
700.59M
from 534.33M
Increased by 31.11%
EPS This Year
0.80
from 0.66
Increased by 21.31%
EPS Next Year
0.99
from 0.80
Increased by 23.64%
EPS and Forward PE are based on non-GAAP adjusted numbers.